UCB v. Cipla — Delaware Court Upholds Nayzilam Seizure Drug Patents After Bench Trial, Blocking Generic Entry
A Delaware federal judge upheld two patents covering UCB’s Nayzilam seizure medication after a bench trial, finding that Cipla failed to prove the patents invalid as anticipated or obvious—preserving UCB’s market exclusivity just as the drug’s orphan drug protection expired.